OpenURL Connection Search

Select item for more details and to access through your institution.

Treatment of Gastroenteropancreatic Neuroendocrine Tumors with Peptide Receptor Radionuclide Therapy.
Published in:
Neuroendocrinology, 2013, v. 97, n. 1, p. 74, doi. 10.1159/000335018
By:
- van Vliet, Esther I.;
- Teunissen, Jaap J.M.;
- Kam, Boen L.R.;
- de Jong, Marion;
- Krenning, Eric P.;
- Kwekkeboom, Dik J.
Publication type:
Article
Neoadjuvant Treatment of Nonfunctioning Pancreatic Neuroendocrine Tumors with [177Lu-DOTA0,Tyr³]Octreotate.
Published in:
Journal of Nuclear Medicine, 2015, v. 56, n. 11, p. 1647, doi. 10.2967/jnumed.115.158899
By:
- van Vliet, Esther I.;
- van Eijck, Casper H.;
- de Krijger, Ronald R.;
- Nieveen van Dijkum, Elisabeth J.;
- Teunissen, Jaap J.;
- Kam, Boen L.;
- de Herder, Wouter W.;
- Feelders, Richard A.;
- Bonsing, Bert A.;
- Brabander, Tessa;
- Krenning, Eric P.;
- Kwekkeboom, Dik J.
Publication type:
Article
Comparison of Response Evaluation in Patients with Gastroenteropancreatic and Thoracic Neuroendocrine Tumors After Treatment with [177Lu-DOTA0,Tyr³]Octreotate.
Published in:
Journal of Nuclear Medicine, 2013, v. 54, n. 10, p. 1689, doi. 10.2967/jnumed.112.117408
By:
- van Vliet, Esther I.;
- Krenning, Eric P.;
- Teunissen, Jaap J.;
- Bergsma, Hendrik;
- Kam, Boen L.;
- Kwekkeboom, Dik J.
Publication type:
Article
Tumor Response Assessment to Treatment with [177Lu-DOTA0,Tyr³]Octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors: Differential Response of Bone Versus Soft-Tissue Lesions.
Published in:
Journal of Nuclear Medicine, 2012, v. 53, n. 9, p. 1359, doi. 10.2967/jnumed.112.102871
By:
- Van Vliet, Esther I.;
- Hermans, John J.;
- de Ridder, Maria A.;
- Teunissen, Jaap J.;
- Kam, Boen L.;
- de Krijger, Ronald R.;
- Krenning, Eric P.;
- Kwekkeboom, Dik J.
Publication type:
Article

Found: 4

Treatment of Gastroenteropancreatic Neuroendocrine Tumors with Peptide Receptor Radionuclide Therapy.

Neoadjuvant Treatment of Nonfunctioning Pancreatic Neuroendocrine Tumors with [<sup>177</sup>Lu-DOTA<sup>0</sup>,Tyr³]Octreotate.

Comparison of Response Evaluation in Patients with Gastroenteropancreatic and Thoracic Neuroendocrine Tumors After Treatment with [<sup>177</sup>Lu-DOTA<sup>0</sup>,Tyr³]Octreotate.

Tumor Response Assessment to Treatment with [<sup>177</sup>Lu-DOTA<sup>0</sup>,Tyr³]Octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors: Differential Response of Bone Versus Soft-Tissue Lesions.